August 10, 2026

The Manager – Listing
BSE Limited,
P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sirs/ Madam,

Sub: Outcome of the Board Meeting held on Monday, August 10, 2026

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

Pursuant to Regulation 30 of the and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby inform that at its meeting held today, i.e. on Monday, August 10, 2026, the Board of Directors ('Board') considered and approved the following:

1. **Unaudited Financial Results**

   The Unaudited Financial Results of the Company for the quarter ended June 30, 2026. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors are enclosed herewith.

   A Press Release with regard to the same is also enclosed herewith.

2. **Appointment of Mr. Arun Krishna and Additional Director**
   Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Arun Krishna (DIN: 11876664), as an Additional Director (Non-Executive) of the Company with effect from August 17, 2026, subject to applicable legal and regulatory requirements.

3. **Change in directorship of Ms. Bhavana Agrawal**

   This is further to the intimation provided on July 21, 2026, whereby the Company communicated the resignation of Ms. Bhavana Agrawal as Chief Financial Officer (Key Managerial Personnel) with effect from close of business hours on August 31, 2026, consequent to her appointment to a regional role within the AstraZeneca Group.

   Based on the recommendation of the Nomination and Remuneration Committee, the Board has consequently approved a change in the designation of Ms. Bhavana Agrawal (DIN: 10485441) from

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Executive Director to Non-Executive Director with effect from September 1, 2026, subject to applicable legal and regulatory requirements.

Further, please find the details as required under the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as an Annexure.

The Meeting commenced at 11:15 A.M. and concluded at 1:40 P.M. (IST).

Please take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**

TANYA SANISH

Digitally signed by TANYA SANISH
Date: 2026.08.10 13:46:35 +05'30'

Tanya Sanish
Company Secretary & Compliance Officer

Encl: As above

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

Independent Auditor's Review Report on the Statement of Unaudited Financial Results

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business park,
Rachenahalli, Outer Ring Road,
Bengaluru - 560045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended June 30, 2026, which are included in the accompanying "Statement of unaudited financial results for the quarter ended 30 June, 2026" (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E300009

Sharmila Ramaswamy
Partner
Membership Number: 215131
UDIN: 26215131PFLNCW5727

Place: Mumbai
Date: August 10, 2026

AstraZeneca Pharma India Limited

Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
CIN: L24231KA1979PLC003563

Statement of unaudited financial results for the quarter ended 30 June 2026

'Rs in millions except for earnings per share data

Sl No.	Particulars	Quarter ended 30/06/2026	Quarter ended 31/03/2026	Quarter ended 30/06/2025	Year ended 31/03/2026
		Unaudited	Refer Note 4	Unaudited	Audited
1	**Income**				
	a) Revenue from operations	6,827.9	5,786.1	5,263.1	22,755.8
	b) Other income	92.3	59.5	112.4	284.9
	Total income	**6,920.2**	**5,845.6**	**5,375.5**	**23,040.7**
2	**Expenses**				
	(a) Cost of materials consumed	-	-	94.9	94.9
	(b) Purchase of stock-in-trade	3,046.2	3,123.1	4,175.9	18,594.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,425.9	819.4	(1,316.7)	(4,883.7)
	(d) Employee benefit expense	791.6	457.0	644.5	2,643.8
	(e) Depreciation and amortisation expense	52.3	56.0	165.7	285.8
	(f) Allowance for expected credit loss (net)	26.0	81.7	22.1	170.9
	(g) Selling, marketing and distribution expense	307.5	301.3	220.2	1,160.0
	(h) Other expenses	741.3	394.5	611.1	2,355.4
	(i) Finance costs	19.5	20.4	7.2	44.9
	Total expenses	6,410.3	5,253.4	4,624.9	20,466.2
3	**Profit before exceptional items and tax (1-2)**	**509.9**	**592.2**	**750.6**	**2,574.5**
4	Add/(Less): Exceptional items (Refer Note 5)	(2.4)	(10.8)	(3.6)	(52.5)
5	**Profit before tax (3+4)**	**507.5**	**581.4**	**747.0**	**2,522.0**
6	**Tax expense**				
	(a) Current tax	108.7	140.3	221.0	591.4
	(b) Tax expense for prior years	-	2.8	-	2.8
	(c) Deferred tax charge / (credit)	19.5	(10.5)	(32.3)	52.6
	Total tax expense	**128.2**	**132.6**	**188.7**	**646.8**
7	**Profit after tax (5-6)**	**379.3**	**448.8**	**558.3**	**1,875.2**
8	**Other comprehensive income/ (loss)**				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurement gains / (losses) on post employment benefit obligations	(4.0)	(63.6)	8.2	(59.4)
	(b) Income tax effect on above	1.0	16.0	(2.1)	15.0
	Other comprehensive income/ (loss), net of income tax	**(3.0)**	**(47.6)**	6.1	**(44.4)**
9	**Total comprehensive income for the period/ year (7+8)**	**376.3**	**401.2**	564.4	**1,830.8**
10	**Paid-up equity share capital** (Face value of Rs 2/- per equity share)	**50.0**	**50.0**	**50.0**	**50.0**
11	**Other Equity**	-	-	-	8,677.9
12	**Earnings per equity share of Rs 2/- each (basic and diluted)**	15.17	17.95	22.33	75.01

Initialled For Identification Purpose Only

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India Limited

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
CIN: L24231KA1979PLC003563

Statement of unaudited financial results for the quarter ended 30 June 2026

Notes:

1 The Statements of financial results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the "Act") [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India.

2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided.

3 During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company's manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and the Company is now in the process of sale of assets related to the manufacturing site.

4 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year i.e 31 March 2026 and the published unaudited year-to-date figures up to the third quarter of the respective financial year i.e 31 December 2025 which were subjected to limited review by the statutory auditors.

5 Exceptional items for the quarter ended 30 June 2026 , 31 March 2026 and 30 June 2025 and year ended 31 March 2026 consists of expenses related to closure of the manufacturing site. (Refer note 3 above)

6 Subsequent to quarter end, the Company received an order from National Pharmaceutical Pricing Authority to deposit an amount of Rs.1,486.58 Million (including interest thereon) alleging overcharging of a combination respiratory drug sold during the period between May 2016 to November 2025. Based on evaluation, Management is of the view that there are reasonable grounds to challenge the same. Accordingly, management has assessed and concluded this matter as a contingent liability and no provision has been recorded in these financial results.

7 Subsequent to the end of the quarter, the Company has received from a third party an amount of Rs. 100 million, recognised as other income in July 2026, towards compensation for commercial losses. Based on its assessment in accordance with Ind AS, the Company has determined that the aforesaid receipt constitutes a non-adjusting event after the reporting period. Accordingly, no adjustment has been made to these financial results.

8 This Statement of unaudited financial results were reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 August 2026. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2026.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Praveen Akkinepally

Praveen Rao Akkinepally
Managing Director

Date: 10 August 2026

Initialled For Identification Purpose Only

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

AstraZeneca Pharma India maintains growth momentum with a strong start to FY2026–27, driven by the strength of our portfolio

Q1 FY2026–27 performance reflects disciplined execution across core therapy areas, important regulatory milestones and strategic partnerships that are helping expand access to innovative healthcare solutions in India

10 August 2026: AstraZeneca Pharma India Limited ("the Company"), a science-led biopharmaceutical company, today announced its financial results for the quarter ended **June 30, 2026**, reporting **30%** growth in total revenue from operations to **INR 6,828 Mn** in **Q1 FY2026–27**. The Company's performance was driven by continued momentum across its core therapy areas-- **Oncology**, **Biopharmaceuticals (CVRM and R&I)** and **Rare Disease**, reflecting the strength of its innovation-led strategy, disciplined execution and focus on improving patient outcomes in India.

During the quarter, the Company strengthened its portfolio through key regulatory approvals, expanded scientific engagement through targeted capability-building initiatives and advanced strategic partnerships that support earlier diagnosis and broader access. These developments reflect AstraZeneca Pharma India's continued focus on addressing unmet medical needs, deepening its presence across priority therapy areas and creating long-term value through science, innovation and sustainable growth.

Financial performance summary:

(Value in INR Mn)

Summary	Q1 2026-27 April-June 2026 (Absolute numbers)
Total revenue from Operations	6,828
Profit before exceptional item and tax	510
Profit after exceptional item and tax	507

TA-wise performance		
Summary	**Q1 2026-27 April-June 2026 (Absolute numbers)**	**Growth vs Q1 2025 -26**
Oncology	4,649	26%
Biopharmaceuticals (CVRM, R&I and V&I)	1,619	36%
Rare Diseases	144	35x

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, *"We delivered 30% growth in the first quarter, bringing our revenue to INR 6,828 Mn. This performance builds on our strong track record of delivering a consistent double-digit growth over the last five years. Our focus remains on investing strategically in opportunities that support sustainable long-term value creation."*

Mr. Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India Ltd., added, *"Our purpose is to push the boundaries of science to deliver life-changing medicines, and this shapes how we serve unmet patient needs in India. The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India."*

Key milestones:

- **Acalabrutinib – Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL):** Received regulatory approval for **acalabrutinib in combination with venetoclax with or without obinutuzumab** for the treatment of patients with previously untreated **chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)**.
- **Acalabrutinib – Mantle cell lymphoma (MCL):** Received regulatory approval for **acalabrutinib in combination with bendamustine and rituximab** for the treatment of adult patients with previously untreated **mantle cell lymphoma (MCL)** who are not eligible for **autologous stem cell transplant (ASCT)**.
- **Trastuzumab deruxtecan – HER2-positive breast cancer:** Received regulatory approval for **trastuzumab deruxtecan in combination with pertuzumab** for the first-line treatment of adult patients with unresectable or metastatic **HER2-positive (IHC3+ or ISH+) breast cancer**.

Strategic initiatives:

- **Government of Telangana MoU – AI-enabled lung cancer screening:** Signed a **Memorandum of Understanding with the Government of Telangana** to introduce **AI-enabled lung cancer screening** across public healthcare facilities in the state. Under the collaboration, AstraZeneca will facilitate deployment of **Qure.ai's AI-powered chest X-ray solution** to support clinicians in identifying high-risk pulmonary nodules and other lung conditions, enabling earlier triage and follow-up. The initiative is expected to roll out across **20 public health facilities** spanning urban and rural settings and includes training and upskilling of healthcare professionals to support effective and sustainable adoption.
- **K+ Connect – Hyperkalaemia management in Heart Failure and Chronic Kidney Disease:** Launched K+ Connect, a pan-India multidisciplinary initiative focused on advancing the management of hyperkalaemia among patients living with heart failure and chronic kidney disease. The initiative brings together clinicians across specialties to support a more coordinated approach towards risk identification, monitoring and management of hyperkalaemia.
- **India Coronary Conquest (ICC) 2026 – Advancing cardiovascular care:** Launched India Coronary Conquest 2026 in collaboration with STEMI India, a clinician-led national complex PCI challenge designed to strengthen evidence-based learning and peer exchange among interventional cardiologists. The initiative aims to support capability building in advanced cardiovascular care through case-based learning and scientific collaboration.

Recognitions:

- **OPPI India Awards 2026:** AstraZeneca Pharma India received the **Medical Excellence Award** for its contributions to Rare Disease and was named **Runner-up in the Marketing Excellence** category for its Hyperkalaemia & Kidney Care initiative in Biopharmaceuticals.
- **ETHRWorld Employee Experience Awards 2026:** AstraZeneca Pharma India was awarded the **Gold Award** in the **Exceptional Employee Experience in Driving Business Impact** category, recognising its commitment to fostering a high-performing, collaborative and purpose-driven workplace.

About AstraZeneca Pharma India Ltd

AstraZeneca Pharma India Limited (AZPIL) is the listed operating company of AstraZeneca in India. A science-led biopharmaceutical company, it focuses on the discovery, development and commercialisation of prescription medicines across key therapy areas including **Oncology**, **Biopharmaceuticals** and **Rare Disease**. With a workforce of over **600 employees** across the country, AZPIL is committed to advancing innovative science, expanding access to differentiated medicines and contributing meaningfully to patient care through strong commercial execution and partnerships across the healthcare ecosystem.

Annexure

Sl. No.	Particulars	Appointment of Mr. Arun Krishna	Change of designation of Ms. Bhavana Agrawal
1.	Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~;	Appointment of Mr. Arun Krishna (DIN: 11876664) as an Additional Director (Non-Executive).	Change of designation of Ms. Bhavana Agrawal (DIN: 10485441) from Executive Director to Non-Executive Director.
2.	Date of appointment and term of appointment	Effective: August 17, 2026 Term of appointment – Not Applicable	Effective: September 1, 2026 Term of appointment – Not Applicable
3.	Brief Profile	Mr. Arun Krishna is Asia Area Vice President in AstraZeneca. As Asia Area Vice President, Arun Krishna oversees country and regional operations for nine markets – India, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam. He has more than 15 years of experience leading teams across clinical development, market access and commercial across global, US and the UK. In his prior role as Vice President, Head of the Lung Cancer Franchise for US Oncology at AstraZeneca, Arun Krishna was responsible for overseeing all lung cancer US sales and commercialization. Arun received a PhD in Biostatistics at North Carolina State University and is a proud father of two children.	Not applicable
4.	Disclosure of relationships between directors	None	None

5.	Affirmation pursuant to circular no. LIST/COMP/14/2018-19 and circular no. NSE/CML/2018/02 dated June 20, 2018 issued by BSE and NSE	Mr. Arun Krishna is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.	Ms. Bhavana Agrawal is not debarred from holding the office of Director by virtue of any SEBI Order or any such Authority.

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628